Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

@article{Spigel2013RandomizedPI,
  title={Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.},
  author={David Robert Spigel and Thomas J. Ervin and Rodryg Adam Ramlau and Davey B. Daniel and Jerome H Goldschmidt and George R. Blumenschein and Maciej Jerzy Krzakowski and Gilles Robinet and Beno{\^i}t Godbert and Fabrice Barl{\'e}si and Ramaswamy Govindan and Taral K. Patel and Sergey V Orlov and Michael S Wertheim and Wei Yu and Jiping Zha and Robert L. Yauch and Premal H. Patel and S C Phan and Amy Christian Peterson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2013},
  volume={31 32},
  pages={4105-14}
}
PURPOSE Increased hepatocyte growth factor/MET signaling is associated with poor prognosis and acquired resistance to epidermal growth factor receptor (EGFR) -targeted drugs in patients with non-small-cell lung cancer (NSCLC). We investigated whether dual inhibition of MET/EGFR results in clinical benefit in patients with NSCLC. PATIENTS AND METHODS Patients with recurrent NSCLC were randomly assigned at a ratio of one to one to receive onartuzumab plus erlotinib or placebo plus erlotinib… CONTINUE READING
Highly Influential
This paper has highly influenced 23 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Related Discussions
This paper has been referenced on Twitter 15 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 172 extracted citations

89Zr-Onartuzumab PET imaging of c-MET receptor dynamics

European Journal of Nuclear Medicine and Molecular Imaging • 2017
View 7 Excerpts
Highly Influenced

Targeting MET in cancer therapy

Chronic diseases and translational medicine • 2017
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…